Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment
Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
In May 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
In May 2025, Incyte Corporation organized a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
In May 2025, Genmab conducted a study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends.
DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies
Marginal Zone Lymphoma Emerging Drugs
Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Marginal Zone Lymphoma Pipeline Report
Coverage- Global
Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Marginal Zone Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
EO2463: Enterome
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
MatchMove Receives Frost & Sullivan's 2025 Singapore Enabling Technology Leadership Recognition for Excellence in Embedded Finance Innovation
Recognition underscores MatchMove's leadership in delivering cutting-edge embedded finance solutions that accelerate digital transformation through API-driven integration, AI, and scalable BaaS models. SAN ANTONIO, July 14, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that MatchMove has been awarded the 2025 Singapore Enabling Technology Leadership Recognition in the embedded finance industry for its outstanding achievements in technological innovation, strategic execution, and customer impact. This recognition highlights MatchMove's commitment to helping businesses modernize financial service delivery, reduce time-to-market, and unlock new revenue streams through its comprehensive embedded finance platform. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. MatchMove excelled in both, demonstrating its ability to align embedded finance innovation with real-world enterprise challenges while scaling solutions seamlessly across diverse verticals and geographies. "In today's digital economy, businesses need agile, intelligent platforms to stay competitive. MatchMove stands out by delivering a powerful embedded finance solution that combines open APIs, cloud infrastructure, and AI-driven automation. Its ability to rapidly deploy secure, scalable financial services makes it a true enabler of digital transformation. Frost & Sullivan is proud to recognize MatchMove with the 2025 Singapore Enabling Technology Leadership Recognition," said Dewi Rengganis, senior ICT industry analyst at Frost & Sullivan. Guided by a long-term strategy rooted in scalable digital innovation and customer-first thinking, MatchMove has redefined how companies integrate financial services. The company's cloud-based, API-native, and low-code/no-code platform enables frictionless adoption for enterprises across retail, eCommerce, FinTech, and public sector domains—empowering them to embed digital wallets, card issuance, cross-border payments, and lending products within their own apps and ecosystems. Innovation lies at the heart of MatchMove's approach. Its full-stack, software-as-a-service (SaaS) banking-as-a-service (BaaS) model bridges the gap between traditional financial infrastructure and modern digital expectations. The platform incorporates real-time transactional data, advanced reporting, and AI-powered fraud detection tools, giving businesses a secure, turnkey "bank-in-a-box" solution without the regulatory and operational complexities of building in-house systems. "We're honored to receive the 2025 Frost & Sullivan Enabling Technology Leadership Recognition for embedded finance in Singapore. This award affirms our mission to democratize financial services and remove barriers for businesses. For over a decade, our 'bank-in-a-box' model has empowered companies to embed banking effortlessly, eliminating the burdens of operational and infrastructure hurdles. This recognition celebrates our team's innovation and the trust our partners place in us to drive smarter, faster, and more inclusive financial solutions." said Amar Abrol, President & Co-Founder at MatchMove. MatchMove's ability to rapidly commercialize emerging technology has positioned it as a key enabler of digital financial services across Asia and the Middle East. Its deployments for clients such as Salmon Philippines, LuLu Money, Maxi-Cash Singapore, and Dubai-based Remotepass highlight its success in delivering measurable business outcomes and accelerating FinTech market entry. Additionally, the acquisition of Singapore's Shopmatic in 2022 further strengthens MatchMove's go-to-market advantage by combining a financial infrastructure with a wide SME customer base. Frost & Sullivan commends MatchMove for setting a high standard in strategic execution, market responsiveness, and technological leadership. The company's ability to help businesses digitize services quickly, enhance user experiences, and achieve regulatory compliance with minimal disruption reflects a strong commitment to reshaping the future of embedded finance. Each year, Frost & Sullivan presents the Enabling Technology Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition acknowledges forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. About MatchMove MatchMove, a Singapore-based fintech company that has emerged as one of Asia's leading Banking-as-a-Service (BaaS) providers, enables businesses to embed financial services directly into their digital solutions. The company operates its proprietary, secure and regulated Banking Wallet OS™ platform across Asian markets, including Singapore, Indonesia, Malaysia, the Philippines, Vietnam, and beyond. MatchMove operates under full regulatory compliance in each market. MatchMove has been recognized with multiple industry awards, including the most recent Frost & Sullivan award for being the leading provider of embedded finance in Singapore across a diverse range of use cases. Always partnering with leading local banks, the company continues expanding its embedded finance solutions across Southeast Asia's rapidly growing digital economy. MatchMove's mission centres on providing innovative financial technology solutions that bridge the gap between traditional banking and modern digital commerce. The company continues to pioneer new approaches to embedded finance across the region's diverse regulatory and market environments. Contact us: Find out more.
Globe and Mail
2 hours ago
- Globe and Mail
Prediction: Nvidia Can Hit a $5 Trillion Market Cap This Year
Key Points Nvidia became the first stock to hit a $4 trillion market cap. The company continues to be the dominant player in AI infrastructure. The stock has a clear path to hit $5 trillion by the end of the year. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) isn't just leading the artificial intelligence (AI) infrastructure boom: It is the boom. Its graphics processing units (GPUs) have become the backbone of AI data centers, while its CUDA software has helped create a huge moat around its business. Over the past two years, data center revenue has exploded by more than 9x, going from $4.3 billion to $39.1 billion. For a company of Nvidia's size, that kind of growth is almost unheard of. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » That momentum has pushed Nvidia past the $4 trillion market cap mark, which is an extraordinary accomplishment. It's also done it quickly, jumping from $1 trillion to $4 trillion in just over a year. At this point, I think predicting that the company will hit $5 trillion by year-end isn't much of a stretch. It's only about a 25% gain from here, and the setup remains strong. Nvidia's valuation is still reasonable. While its forward price-to-earnings (P/E) ratio has crept up to 38 times based on this year's analyst estimates, its forward price/earnings-to-growth (PEG) ratio is just more than 0.8, with PEGs below 1 signaling a stock is undervalued. Meanwhile, investors will soon start to turn to 2026 estimates when looking at valuations, and the stock trades at only a 28.5 P/E ratio and less than a 0.8 PEG on next year's analyst consensus. A 25% increase in Nvidia's stock price is getting you to around a 35.5 times P/E and a 1 PEG, which would still be reasonable. The CUDA moat Nvidia's biggest advantage comes from its CUDA software platform. GPUs were originally designed to speed up graphics rendering in video games. However, Nvidia saw a bigger opportunity and built CUDA as a way to let developers program its chips for other purposes. Although GPU usage for other tasks didn't take off immediately, Nvidia smartly pushed CUDA into universities and research labs, which is where early AI work began. That long-term bet eventually paid off in a big way. CUDA became the platform that developers learned to program GPUs on, and the more it was used, the more tools were built for it. That network effect helped Nvidia extend its lead, and last quarter it captured a 92% market share in GPUs, largely due to CUDA. AMD 's ROCm software platform has improved, but it's still miles behind in terms of ease of use, documentation, and developer support. Data center demand isn't slowing down Nvidia's core market remains AI training and inference, and the demand for its chips shows no signs of easing. Companies are spending aggressively to build out large language models, while cloud computing companies and other hyperscalers (companies with massive data centers) are racing to scale out their infrastructure. Nvidia, meanwhile, is the company powering this buildout. Nvidia's CEO Jensen Huang has predicted that data center spending tied to AI will exceed $1 trillion by 2028. Not all of that will go to Nvidia, but given its leadership in GPUs, the company is well positioned to take a big piece. It also continues to innovate at a rapid pace. Its chip release cycle has sped up, with new architectures set to be introduced every year instead of every two. That should help lock in its lead and keep it ahead of rivals. Even if data center growth slows from here -- and at some point it will -- Nvidia still has more levers to pull. Data centers aren't its only growth engine. The company's auto business is gaining traction. Last quarter, auto revenue surged 72% to $567 million. That's a fraction of its data center business, but Nvidia expects it to hit $5 billion this year. The ramp-up in the auto sector is coming from robotaxis and smart vehicles. Alphabet 's Waymo uses Nvidia chips in its robotaxi fleet, and it's now running more than 250,000 paid rides per week. That's just the start. Mercedes, Toyota, and Volvo are all using Nvidia's DRIVE platform for advanced driver assistance and autonomy. General Motors and Hyundai, meanwhile, are using Nvidia technology in their smart factory initiative. Nvidia projected in 2022 that its auto opportunity could reach $300 billion. Given the advancements in autonomous driving, that number doesn't look farfetched. Is the stock a buy? With the stock already hitting a $4 trillion market cap, a move to $5 trillion is well within reach. That's a solid 25% return from current levels, which would still make the stock a buy. As long as AI infrastructure spending continues to ramp up, Nvidia is a stock you want to own. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Geoffrey Seiler has positions in Alphabet. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, and Nvidia. The Motley Fool recommends General Motors. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
SILVER ONE COMMISSIONS GROUND GEOPHYSICAL SURVEY ON ITS PHOENIX SILVER PROJECT, ARIZONA
VANCOUVER, BC , July 14, 2025 /CNW/ -- Silver One Resources Inc. (TSXV: SVE) (OTCQX: SLVRF) (FSE: BRK1) ("Silver One" or the "Company") is pleased to announce that it has engaged Zonge International, Inc., to conduct a ground geophysical Induced Polarization (IP) and Magnetotelluric (MT) survey on its 100% owned Phoenix Silver project in Arizona . Both IP and MT are effective electrical geophysical methods useful to detect underground metallic minerals, especially disseminated sulfides, and structures that may be host to mineralization. This is especially important in the southern portion of the property where previous magnetic and ZTEM surveys, in combination with multiple select high-grade copper and silver samples are suggestive of a copper-silver system at depth ( See Figures 1 and 2 and news release of February 20, 2025 ). Owing to safety reasons related to fire hazard in the project's area, the survey will be scheduled as soon as Forest Service fire restrictions are lifted. The planned survey consists of 50-line km of ground IP and MT over robust copper targets. These targets were identified using Geotech's targeting algorithm that combines several datasets including, resistivity derived from the ZTEM survey, magnetic features, geology, structure, mine sites and copper showings (see Company's news release of February 20, 2025 and Figures 1 and 2). These targets have never been drill tested, and their importance is highlighted by their location along the north-eastern portion of the prolific Miami-Inspiration copper belt, which hosts Rio Tinto-BHP's Resolution deposit to the southwest and BHP's Ocelot discovery to the northeast (Figure 1). The IP and MT survey will target vertical depths of 600 metres and 1,500 metres respectively. This survey, in conjunction with previous field investigations, will allow the Company to define and prioritize targets for future drilling. Silver Exploration The company plans to continue with further evaluation of silver targets, especially the 417 area and the long northeast-trending train of silver nuggets located in the northern part of the property. A detailed gravity survey is planned over the 417 area drilled in 2024 to assist in defining the location of massive silver bodies (see Company's news release of February 24, 2025 and Figure 2) and guide future drilling. At the Nuggets North area, planned work includes mapping, sampling, and trenching subject to Forest Service permitting. Candelaria Project Update The Company is also pleased to announce that work at the Candelaria project is on schedule, continuing with metallurgical investigations to optimize silver and gold recoveries, and a Preliminary Economic Assessment study (PEA) scheduled to be completed by the end of the year. Qualified Person The technical content of this news release has been reviewed and approved by Robert M. Cann , P. Geo, a Qualified Person as defined by National Instrument 43-101 and an independent consultant to the Company. About Silver One Silver One is focused on the exploration and development of quality silver projects. The Company holds a 100% interest in its flagship project, the past-producing Candelaria Mine located in Nevada . Potential reprocessing of silver from the historic leach pads at Candelaria provides an opportunity for possible near-term production. Additional opportunities lie in previously identified high-grade silver intercepts down-dip and potentially increasing the substantive silver mineralization along-strike from the two past-producing open pits. The Company owns 636 lode claims and five patented claims on its Cherokee project located in Lincoln County, Nevada , host to multiple silver-copper-gold vein systems, traced to date for over 11 km along-strike. Silver One also owns a 100% interest in the Silver Phoenix Project. The Silver Phoenix Project is a very high-grade native silver prospect that lies within the "Arizona Silver Belt", immediately adjacent to the prolific copper producing area of Globe , Arizona. For more information, please contact: Silver One Resources Inc. Gary Lindsey - VP, Investor Relations Phone: 604-974‐5274 Mobile: (720) 273-6224 Email: gary@ Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Silver One cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond Silver One's control. Such factors include, among other things: risks and uncertainties relating to Silver One's limited operating history, ability to obtain sufficient financing to carry out its exploration and development objectives on its mineral properties, obtaining the necessary permits to carry out its activities and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Silver One undertakes no obligation to publicly update or revise forward-looking information.
